Overview | Mechanism of Action | Safety and Side Effects | Clinical Trials | Brochures | References         Leeb BF, Schweitzer H, Montag K et al. A meta-analysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol 2000; 27: 205-211. Mazieres B, Combe B, Phan Van A, et al. Chondroitin sulphate in osteoarthritis of the knee ; a prospective, double-blind, placebo-controlled multicenter clinical study. J Rheumatol 2001; 28: 173-181. Chandler F, ed. Herbs: Everyday Reference for Health Professionals. Canadian Pharmacists Association and the Canadian Medical Association: Ottawa (ON); 2000. Jellin JM, Batz F, Hitchens K, ed. Pharmacist’s Letter/Prescriber’s Letter Natural Medicines Comprehensive Database. Stockton (CA): Therapeutic Research Faculty; 2003. Bourgeois P, Chales G, Dehais J, Delcambre B, Kuntz JL, Rosenberg S. Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 x 400 mg/day vs placebo. Osteoarthritis Cartilage. 1998 May; 6(Suppl A): 25-30. Bucsi L, Poor G. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage. 1998 May; 6(Suppl A): 31-6. Shankland WE. The effects of glucosamine and chondroitin sulphate on osteoarthritis of the TMJ: a preliminary report of 50 patients. J Craniomandib Pract 1998; 16(4): 230-235. Uebelhart D, Thonar EJ, Delmas PD, Chant Raine A, Vignon E. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage 1998 May; 6(Suppl A): 39-46. Leeb BF, Petera P, Neumann K. Results of a multicenter study of chondroitin sulphate(Condrosulf) use in art hoses of the finger, knee and hip joints. [German]. Wien Med Wochenschr 1996; 146(24): 609-14. Morreale P, Manopulo R, Galati M, et al. Comparison of the anti-inflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. J Rheumatol 1996; 23(8): 1385-91. Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia (electronic version). Denver (CO): Micromedex Inc.; 1991. Liesegang TJ. Viscoelastic substances in ophthalmology. Surv Opthalmol 1990; 34: 268-293. Kerzberg EM, Roldan EJ, Castella G, et al. Combination of gylcosaminoglycans and acetylsalicylic acid in knee osteoarthritis. Scand J Rheumatol; 1987; 16(5): 377-80. Verbruggen G, Goemaere S, Veys E. Chondroitin sulfate: S/MOAD (structure/disease modifying antiosteoarthritis drug) in the treatment of finger joint OA. OsteoarthritisCartilage 1998; 6(suppl A): 37-38. Murray MT. Encyclopedia of Nutritional Supplements: The Essential Guide for Improving your Health Naturally. Rocklin (CA): Prima Publishing; 1996. Morrison LM. Reduction of ischemic coronary heart disease by chondroitin sulphate A. Angiology 1971; 22: 165-174. Morrison LM, Enrick NL. Coronary heart disease: reduction of death rate by chondroitin sulphate. Angiology 1973; 24: 269-287. ChemBioPrint: The discovery and standardization of beneficial natural health product mixtures. CVT Internal Report. Resnick LM, Lewanczuk RZ, Laragh JH, Pang PKT. Parathyroid hypertensive factor-like activity in human essential hypertension: relationship to plasma renin activity and dietary salt sensitivity. J. Hypertens 1993; 11: 1235-1242. Lewanczuk RZ, Fields ALA, Shan J, Benishin CG, Pang PKT. Manuscript in preparation. Ho M-S, Lewanczuk RZ, The B-H, Lee S-C, Pang PKT. Parathyroid hypertensive factor and non-insulindependent diabetes mellitus. J. Cardiovasc. Pharmacol. 1994; 23(Suppl. 2): S31-S34. Shan J, Benishin CG, Lewanczuk RZ, Pang PKT. Mechanism of the vascular action of parathyroid hypertensive factor. J. Cardiovasc. Pharmacol. 1994; 23(Suppl. 2): S1-S8 Lee A, Langer R. Shark cartilage contains inhibitors of tumor angiogenesis. Science 1983; 221: 1185-1187.
Contact UsLegal Terms & ConditionsPrivacy PolicySite Map       * Trademarks owned by CV Technologies Inc. This website is not intended for residents of the United States.